Bayer’s factor XIa inhibitor slashed the risk of recurrent stroke in a late-stage trial in certain patients, breathing new life into a class of drugs that has suffered a string of high-profile failures.
The unexpected …
Plus, news about Bayer’s Kerendia, Eli Lilly’s Ebglyss and Alto Neuroscience: 📈 CytomX’s colorectal cancer data: The biotech tested multiple doses of its antibody-drug conjugate
A maternal care startup offering virtual and in-person care just raised $12 million in new funding after dropping commercial insurers to focus on Medicaid, Endpoints
AstraZeneca’s cancer immunotherapy Imfinzi has been approved in the EU for use before and after surgery for early-stage gastric cancer.
CirCode Biomed, a Chinese startup working on an experimental class of genetic medicines known as circular RNA, has received the FDA’s blessing to begin a
A German study has stoked debate about the merits of screening for prostate cancer, which is lagging behind breast cancer screening in Europe.
Bayer’s factor XIa inhibitor slashed the risk of recurrent stroke in a late-stage trial in certain patients, breathing new life into a class of drugs that has suffered a string of high-profile failures.
The unexpected …